Skip to main content
. 2017 Sep 12;89(11):1107–1116. doi: 10.1212/WNL.0000000000004313

Figure 3. Brain volume loss over 5 years in alemtuzumab patients.

Figure 3

Median yearly percentage change in BPF is shown for all patients who received alemtuzumab 12 mg in the core CARE-MS I study and then enrolled in the extension. BPF = brain parenchymal fraction; CARE-MS = Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis.